روند روزانه سهام شرکت
AcelRx Pharmaceuticals, Inc.
این نمودار بصورت روزانه به روز رسانی می گردد
|نام شرکت||نماد||سرمایه (میلیون دلار)||کشور||عرضه اولیه||زیر مجموعه|
|AcelRx Pharmaceuticals, Inc.||ACRX||۱۶۷٫۹۱||United States||۲۰۱۱||Major Pharmaceuticals|
We are a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain. Our lead product candidate, DSUVIA (known as ARX-04 outside of the United States), and our follow-on product candidate, ZALVISO, utilize sublingual sufentanil, delivered via a non-invasive route of administration. We anticipate developing a distribution capability and commercial organization in the United States to market and sell DSUVIA in the United States by ourselves, and potentially, in certain European Economic Area, or EEA, countries, either alone or with partners. In geographies where we decide not to commercialize ourselves, we would seek to out-license commercialization rights. We intend to seek regulatory approval for ZALVISO in the United States and, if successful, potentially promote ZALVISO as a follow-on product to DSUVIA, either by ourselves or with strategic partners.